

Elevated renin activity and change in sleep apnea with primary aldosteronism

Yonekazu Kidawara, M.D., Ph.D.¹ Manabu Kadoya, M.D., Ph.D.¹ Masataka Igeta, Ph.D.² Miki Kakutani-Hatayama, M.D., Ph.D.¹ Akiko Morimoto, M.D., Ph.D.¹ Akio Miyoshi, M.D., Ph.D.¹ Akinori Kanzaki, M.D., Ph.D.¹ Kosuke Konishi, M.D., Ph.D.¹ Takashi Daimon, Ph.D.² and Hidenori Koyama M.D., Ph.D.¹

¹Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan

²Department of Biostatistics, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan

Short title: Primary aldosteronism and sleep apnea

Corresponding author:

Manabu Kadoya, M.D., Ph.D.

Department of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University

1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

Tel: +81 798 45 6473; Fax: +81 798 45 6443

Email: mkadoya@hyo-med.ac.jp

ORCID: 0009-0004-3541-5270

Total words (excluding abstract and references): 2301

ABSTRACT

Background: The prevalence of obstructive sleep apnea (OSA) is higher in patients with primary aldosteronism (PA), while elevated renin activity after treatment is associated with a lower risk of cardiovascular events. However, the association of PA with degree of OSA remains unclear and it is not known whether elevated renin activity in PA patients is associated with change in apnea condition.

Methods: Cross-sectional relationships between PA (n=176) and degree of OSA classified by apnea-hypopnea index (AHI) with use of an apnomonitor were investigated, with the results compared with those obtained with non-PA patients (n=418). Additionally, the effects of elevated renin activity on change in AHI were prospectively examined in 45 patients with PA.

Results: Patients with PA were found to be significantly associated with severe OSA even after adjustment for other clinical risk factors (odds ratio 2.08, 95% confidence interval 1.09-3.95, $p = 0.025$) as compared to those without PA. Furthermore, the logarithm of the renin activity after treatment and change in AHI before and after treatment were significantly negatively correlated, with Pearson's correlation coefficient ($r = -0.364$, $p = 0.014$).

Conclusions: Severe OSA is more commonly seen in PA patients with hypertension as compared to patients without PA, and elevated renin activity may contribute to improvement of sleep apnea in patients with PA.

Keywords: primary aldosteronism, sleep apnea, AHI, renin activity

56

57 **Introduction**

58 Primary aldosteronism (PA) is recognized as one of the most common causes of
59 secondary hypertension, and affected individuals have also been shown to have
60 a higher risk for cardiovascular events and mortality independent of blood
61 pressure level as compared to patients with essential hypertension (EH)¹⁻⁴.
62 Obstructive sleep apnea (OSA), another well-known cause of hypertension, has
63 also been found to contribute to increased risk of cardiovascular morbidity and
64 mortality⁵⁻⁷. In patients with PA, the prevalence of OSA has been reported to be
65 as high as 60% to 80%⁸. Additionally, those patients have a tendency for higher
66 OSA prevalence as compared to patients without PA who are hypertension
67 resistant⁹. Another report regarding risk of PA showed that individuals with
68 maintained suppression of renin activity had increased risk of cardiovascular
69 events and death¹⁰. Therefore, unsuppressed renin activity is now recognized
70 as a therapeutic goal for PA patients, though it remains unclear whether elevated
71 renin activity is associated with changes related to apnea. The present study
72 was performed as a cross-sectional examination of the association of PA with

degree of OSA and also prospectively investigated the effect of elevated renin

activity on sleep apnea.

Methods

Study design and participants

From October 2010 to November 2020, 1151 patients assessed for diagnosis of PA and OSA were enrolled in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) study. Out of these, 781 were hypertensive patients including those with PA. For the present study, those with autonomous cortisol secretion, pheochromocytoma, primary hyperparathyroidism, estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m², or dialysis treatment were excluded (n=128). Additionally, 59 with missing baseline data regarding assessment of OSA were also excluded. Finally, 594 were enrolled, and divided into the PA (n=176) and non-PA (n=418) groups. Of those with PA, 45 patients were simultaneously reassessment for renin activity and sleep apnea within five years (**Figure 1**). HSCAA study, which has received approved by the institutional ethical committee of Hyogo Medical University (approval No. 2351), was used and informed written consent was obtained from each participant.

91

92 **Plasma biochemical parameters**

93 Blood samples were obtained in the morning after an overnight fast and then

94 quickly centrifuged to obtain plasma. Whole blood was used for hemoglobin A1c,

95 EDTA plasma for glucose and lipids, and serum for other biochemical assays.

96 Glucose measurements were performed using a glucose oxidase method and

97 an enzymatic method was used to determine serum creatinine concentration.

98 Estimated glomerular filtration rate in each patient was calculated using an

99 equation for Japanese subjects, as follows: estimated glomerular filtration rate

100 $(\text{mL/min per } 1.73 \text{ m}^2) = 194 \times \text{age (years)}^{-0.287} \times \text{S-creatinine}^{-1.094}$ (if female, $\times 0.739$).

101 Plasma renin activity (PRA) and plasma aldosterone concentration (PAC) were

102 measured using an enzyme immunoassay with the patient at rest in a supine

103 position for 30 minutes.

104

105 **Diagnosis of primary aldosteronism**

106 Patients were diagnosed with PA based on a PAC (pg/mL) to PRA (ng/mL/hour)

107 ratio (ARR) ≥ 200 at screening and at least one positive result from confirmatory

108 tests for PA diagnosis (saline infusion test, captopril challenge test,

furosemide-upright test) at the time of admission, according to previously

reported guidelines ^{11,12}.

Assessment of sleep apnea

To determine the presence of sleep apnea, an apnomonitor device (SAS-2100,

Nihon Kohden, Tokyo, Japan; supplied by Teijin, Tokyo, Japan) was used to

provide apnea-hypopnea index (AHI) values. Criteria presented in The American

Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated

Events, version 2.1, were used for analysis of respiratory events, as follows.

Apnea was defined when the amplitude ratio to normal breathing was $\leq 10\%$ with

air flow lasting ≥ 10 seconds, and hypopnea when the amplitude ratio to normal

breathing was $\leq 70\%$ with air flow lasting ≥ 10 seconds and associated with a 4%

decrease in oxygen saturation. AHI was calculated as the average number of

apnea and hypopnea episodes per hour. When the decrease was 3% or more

per second or the sensor was disconnected, the result was considered an

artifact and excluded from analysis. The degree of sleep apnea was classified

based on AHI values as none (0 to <5), mild (5 to <15), moderate (15 to <30), or

severe (≥ 30) ¹³.

127

128 **Statistical analyses**

129 For comparisons of mean and median values of continuous variables for the
130 baseline clinical characteristics between PA status (PA and non-PA), and also
131 suppressed renin activity status in patients with PA (remained suppressed and
132 unsuppressed), Welch's t-test or the Mann-Whitney U-test was used. Fisher's
133 exact test was used for categorical variables. Multivariable logistic regression
134 analysis was used to calculate odds ratio (OR) and 95% confidence interval (CI)
135 values for the associations of degree of OSA with PA as compared to the non-PA
136 group adjusting for clinical factors, including potential causal factors for sleep
137 apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and renal function. In
138 addition, a Pearson's correlation coefficient was calculated to evaluate the
139 association between the change of AHI and elevation of the renin activity in PA
140 patients. The logarithmic transformation was performed to the renin activity for a
141 normal approximation. All statistical analyses were performed with EZR, version
142 1.61 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) and
143 SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). All reported P
144 values are two-sided and considered to be statistically significant at <0.05

without adjustment for multiplicity.

Results

Baseline clinical characteristics

The baseline characteristics of the present patients after dividing into the PA and non-PA groups are shown in **Table 1**. The distribution of degree of sleep apnea in those with PA was as follows: normal (AHI <5), 26.7%; mild (AHI 5 to <15), 38.6%; moderate (AHI 15 to <30), 18.8%; and severe (AHI ≥30), 15.9%. Patients with PA exhibited higher levels of systolic BP, diastolic BP, and plasma aldosterone concentration, lower levels of fasting plasma glucose, HbA1c, and plasma renin activity, and lower prevalence of diabetes and dyslipidemia, as compared to the non-PA group.

The baseline clinical characteristics of the patients classified by degree of OSA are presented in **Table 2**. Comparisons were also made between patients classified according to degree of OSA and those without OSA. There were no clinically significant differences in regard to smoking, diastolic BP, LDL-cholesterol, PRA, PAC, or use of anti-hypertensive drugs such as

calcium-channel blocker and diuretic agent between patients with OSA regardless of severity as compared to those without OSA. Patients with OSA showed higher levels of BMI, systolic BP, FPG, and HbA1c, and a higher prevalence for male gender and diabetes, and lower level of eGFR as compared to patients without OSA. Those with mild or moderate OSA were older than those without OSA. As compared to patients without OSA, those with moderate or severe OSA had lower levels of HDL, higher levels of TG, and a higher prevalence of dyslipidemia. Users of α blocker anti-hypertensive drugs were more frequently noted among patients with severe OSA as compared to those without OSA. Furthermore, the prevalence of PA tended to be higher in patients with severe OSA, though the difference was not significant as compared to patients classified with other levels of OSA.

Relationship of PA with degree of OSA

Results of multivariable logistic analysis performed to examine the associations of PA with each level of OSA as compared to non-PA patients are shown in **Table 3**. This analysis was fully adjusted for clinical factors, including potential causal factors for sleep apnea, i.e., age, male gender, BMI, systolic BP, HbA1c, and

renal function. PA was shown to have a significant association with only severe OSA. These results suggest that patients with PA are more likely than hypertensive patients without PA to be complicated by severe sleep apnea under adjustment of the potential causal factors for sleep apnea.

Effects of elevated renin activity on change of sleep apnea

Renin activity and AHI were reevaluated after a mean of 2.5 ± 1.6 years in 45 PA patients. Pearson's correlation coefficient were used to evaluate the association between the logarithm of the renin activity at reevaluation and amount of change in AHI, as shown in **Figure 2**. This relationship was significantly negatively correlated ($r = -0.364$, $p = 0.014$).

Discussion

This is the first study to assess cross-sectional associations among PA patients with various degrees of OSA. Moreover, the effects of remaining suppressed renin activity on sleep apnea in patients with PA were prospectively examined. PA was found to be strongly associated with severe sleep apnea under adjustment of the potential causal factors for sleep apnea. Additionally, they

show that elevated renin activity can potentially prevent the progression of sleep

apnea in patients with PA.

Epidemiological studies have found that PA is a disease that can cause sleep

apnea. Among patients with resistant hypertension, the degree of OSA has been

reported to be higher in those with hyperaldosteronism ¹⁴. The present results

show an association of PA with severe sleep apnea under adjustment of the

potential causal factors for sleep apnea. Previously, it was suggested that

excessive aldosterone secretion causes inappropriate sodium and fluid retention

⁶. Furthermore, mechanisms related to fluid movement from the lower

extremities to the neck caused by edema of the upper airway may contribute to

the etiology of OSA ¹⁵. Another study noted that patients with OSA who

underwent diuretic treatment showed significantly improved upper airway caliber

and OSA, further implicating pharyngeal edema as a cause of upper airway

collapse during sleep ¹⁶. Moreover, a volumetric analysis technique used with

magnetic resonance imaging demonstrated that volume of the tongue and lateral

walls were independent factors related to increased risk of OSA ¹⁷. Impairment of

ventilatory-control mechanisms can also contribute to modulation of pharyngeal

collapsibility during sleep, thus suggesting a role for central nervous system input, which may be influenced by humoral factors ¹⁸⁻²⁰. Furthermore, basic research results have indicated that aldosterone has a central role in increased brain renin-angiotensin activity, oxidative stress, and sympathetic drive ²¹. Therefore, in addition to pharyngeal edema caused by inappropriate sodium and fluid retention related to hyperaldosteronism, disruptions in normal central respiratory mechanisms by aldosterone-induced activation of central receptors may potentially contribute to the association between PA and sleep apnea severity.

Aldosterone receptor antagonists are used as therapeutic agents in patients with PA. Such medication has also been indicated as effective for not only improving hypertension but also preventing complications, including cardiovascular events. Spironolactone treatment for patients with resistant hypertension has been reported to significantly decrease AHI level ²². As for pharmacological treatment for PA, elevated renin activity has been shown useful to prevent development of cardiovascular events, cardiovascular death, and renal dysfunction, thus elevated renin activity is considered to be a therapeutic goal. A possible

mechanism underlying the association between elevated renin activity and sleep apnea following therapeutic intervention may be inhibition of mineralocorticoid receptor activation by aldosterone antagonists or an adrenalectomy for aldosterone-producing adenoma treatment²³. Elevated renin activity is used as an indicator of suppressed mineralocorticoid receptor activation. Results of the present study indicate that elevated renin activity leads to prevent progress of sleep apnea.

This study has several limitations. First, the findings may not be generalizable to all patients with different blood pressure status. Second, the present cohort did not take into account the effect of change in body weight, as that was not possible to track. Nevertheless, the present findings are considered to provide important initial information for clarification of the association of PA with sleep apnea. Moreover, there was a significant negative correlation between the renin activity after treatment and change in AHI before and after treatment. The results suggest that the increase in renin activity reflects suppression of aldosterone action, which may lead to improvement of sleep apnea via improvement of pharyngeal edema.

253

254 **Conclusion**

255 As compared to hypertensive patients without PA, patients with PA are more
256 likely to have severe sleep apnea. Furthermore, elevated renin activity may
257 contribute to improvement of sleep apnea in patients with PA.

258

259 **Perspectives**

260 PA appears to play a fundamental role in development of sleep apnea. The
261 elevated renin activity is used as an indicator of the effects of PA treatment goals
262 as well as need for prevention of various complications. The present study
263 investigated the association of PA with degree of OSA as compared to non-PA
264 patients with hypertension and is the first to report a relationship between
265 elevated renin activity and changes in sleep apnea in PA patients. The results
266 provide important initial insight regarding the association of PA with degree of
267 sleep apnea as well as for determining whether elevated renin activity has
268 effects on sleep apnea in patients with PA.

269

270 **Acknowledgements**

The authors are grateful for the excellent technical assistance provided by Tomoe Ushitani and Ai Matsumoto. We also wish to thank the other investigators and staff members, as well as the participants of the HSCAA study for their valuable contributions.

Funding

JSPS KAKENHI grants (24K19043 to Y. Kidawara, 20K18944 to A. Mrimoto) and Hyogo Medical University (Hyogo Innovative Challenge to H. Koyama) were received.

Disclosures

There no conflicts of interest or commercial affiliations to disclose.

Data Availability

The datasets generated during and/or analyzed for the current study are not publicly available, though can be provided by the corresponding author upon reasonable request.

Novelty and Relevance

What is new?

This study sheds light on the currently incompletely understood association between PA and degree of OSA in hypertensive patients and effect of elevated renin activity for change in sleep apnea in patients with PA. An increased risk of severe OSA is revealed in patients with PA. Furthermore, it indicated that elevated renin activity following treatment can possible to prevent sleep apnea progression.

What Is Relevant?

Our results provide important initial findings to unveil the pathophysiological factors for PA and OSA.

Clinical/Pathophysiological Implications?

PA is an important risk factor for severe OSA in hypertensive patients, and elevated renin activity following treatment is negatively correlated with progression of sleep apnea. These knowledge could improve the prediction and progression of sleep apnea in patients with PA.

References

1. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol.* 2005;45:1243-1248. doi: 10.1016/j.jacc.2005.01.015

- 311 2. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular
312 complications in patients with aldosterone producing adenoma in Japan:
313 comparative study with essential hypertension. The Research Committee
314 of Disorders of Adrenal Hormones in Japan. *J Endocrinol Invest.*
315 1995;18:370-373. doi: 10.1007/BF03347840
- 316 3. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi
317 LA. Cardiovascular outcomes in patients with primary aldosteronism after
318 treatment. *Arch Intern Med.* 2008;168:80-85. doi:
319 10.1001/archinternmed.2007.33
- 320 4. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications
321 associated with primary aldosteronism: a controlled cross-sectional study.
322 *Hypertension.* 2013;62:331-336. doi:
323 10.1161/HYPERTENSIONAHA.113.01060
- 324 5. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as
325 a risk factor for coronary events or cardiovascular death. *Sleep Breath.*
326 2010;14:131-136. doi: 10.1007/s11325-009-0298-7
- 327 6. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A,
328 Daniels S, Floras JS, Hunt CE, Olson LJ, et al. Sleep apnea and

cardiovascular disease: an American Heart Association/american College
Of Cardiology Foundation Scientific Statement from the American Heart
Association Council for High Blood Pressure Research Professional
Education Committee, Council on Clinical Cardiology, Stroke Council, and
Council On Cardiovascular Nursing. In collaboration with the National
Heart, Lung, and Blood Institute National Center on Sleep Disorders
Research (National Institutes of Health). *Circulation*. 2008;118:1080-1111.
doi: 10.1161/CIRCULATIONAHA.107.189375

7. Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive sleep apnea
and risk of cardiovascular disease and all-cause mortality: a
meta-analysis of prospective cohort studies. *Int J Cardiol*.
2013;169:207-214. doi: 10.1016/j.ijcard.2013.08.088

8. Florczak E, Prejbisz A, Szwench-Pietrasz E, Sliwiński P, Bieleń P,
Klisiewicz A, Michałowska I, Warchoń E, Januszewicz M, Kała M, et al.
Clinical characteristics of patients with resistant hypertension: the
RESIST-POL study. *J Hum Hypertens*. 2013;27:678-685. doi:
10.1038/jhh.2013.32

9. Prejbisz A, Florczak E, Klisiewicz A, Dobrowolski P, Janaszek-Sitkowska

- 347 H, Bieleń P, Szwench-Pietrasz E, Warchoń-Celińska E,
348 Kołodziejczyk-Kruk S, Janas J, et al. Relationship between primary
349 aldosteronism and obstructive sleep apnoea, metabolic abnormalities and
350 cardiac structure in patients with resistant hypertension. *Endokrynol Pol.*
351 2013;64:363-367. doi: 10.5603/EP.2013.0019
- 352 10. Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A.
353 Cardiometabolic outcomes and mortality in medically treated primary
354 aldosteronism: a retrospective cohort study. *Lancet Diabetes Endocrinol.*
355 2018;6:51-59. doi: 10.1016/S2213-8587(17)30367-4
- 356 11. Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa
357 S, Ichijo T, Otsuki M, Omura M, et al. Japan Endocrine Society clinical
358 practice guideline for the diagnosis and management of primary
359 aldosteronism 2021. *Endocr J.* 2022;69:327-359. doi:
360 10.1507/endocrj.EJ21-0508
- 361 12. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T,
362 Hoshida S, Ikeda S, Ishimitsu T, et al. The Japanese Society of
363 Hypertension Guidelines for the Management of Hypertension (JSH
364 2019). *Hypertens Res.* 2019;42:1235-1481. doi:

365 10.1038/s41440-019-0284-9

366 13. Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K,
367 Harrod CG. Clinical Practice Guideline for Diagnostic Testing for Adult
368 Obstructive Sleep Apnea: An American Academy of Sleep Medicine
369 Clinical Practice Guideline. *J Clin Sleep Med*. 2017;13:479-504. doi:
370 10.5664/jcsm.6506

371 14. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding
372 SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep
373 apnea is related to aldosterone status in subjects with resistant
374 hypertension. *J Clin Sleep Med*. 2010;6:363-368.

375 15. Shiota S, Ryan CM, Chiu KL, Ruttanaumpawan P, Haight J, Arzt M,
376 Floras JS, Chan C, Bradley TD. Alterations in upper airway
377 cross-sectional area in response to lower body positive pressure in
378 healthy subjects. *Thorax*. 2007;62:868-872. doi:
379 10.1136/thx.2006.071183

380 16. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin
381 A. Diuretics in obstructive sleep apnea with diastolic heart failure. *Chest*.
382 2007;132:440-446. doi: 10.1378/chest.07-0311

- 383 17. Schwab RJ, Pasirstein M, Pierson R, Mackley A, Hachadoorian R, Arens
384 R, Maislin G, Pack AI. Identification of upper airway anatomic risk factors
385 for obstructive sleep apnea with volumetric magnetic resonance imaging.
386 *Am J Respir Crit Care Med.* 2003;168:522-530. doi:
387 10.1164/rccm.200208-866OC
- 388 18. Wolk R, Johnson BD, Somers VK. Leptin and the ventilatory response to
389 exercise in heart failure. *J Am Coll Cardiol.* 2003;42:1644-1649. doi:
390 10.1016/j.jacc.2003.06.007
- 391 19. Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and
392 hypocapnia on sympathetic nerve responses to hypoxia in normal
393 humans. *J Appl Physiol (1985).* 1989;67:2095-2100. doi:
394 10.1152/jappl.1989.67.5.2095
- 395 20. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of
396 hypoxia and hypercapnia on ventilation and sympathetic activity in
397 humans. *J Appl Physiol (1985).* 1989;67:2101-2106. doi:
398 10.1152/jappl.1989.67.5.2101
- 399 21. Zhang ZH, Yu Y, Kang YM, Wei SG, Felder RB. Aldosterone acts centrally
400 to increase brain renin-angiotensin system activity and oxidative stress in

normal rats. *Am J Physiol Heart Circ Physiol*. 2008;294:H1067-1074. doi:

10.1152/ajpheart.01131.2007

22. Yang L, Zhang H, Cai M, Zou Y, Jiang X, Song L, Liang E, Bian J, Wu H,

Hui R. Effect of spironolactone on patients with resistant hypertension

and obstructive sleep apnea. *Clin Exp Hypertens*. 2016;38:464-468. doi:

10.3109/10641963.2015.1131290

23. Valaiyapathi B, Calhoun DA. Role of Mineralocorticoid Receptors in

Obstructive Sleep Apnea and Metabolic Syndrome. *Curr Hypertens Rep*.

2018;20:23. doi: 10.1007/s11906-018-0819-5

Figure legends

Figure 1. Flow of subject selection.

eGFR, estimated glomerular filtration rate; PA, primary aldosteronism.

Figure 2. Association between renin activity following treatment and

amount of changes in AHI.

Correlation coefficient and p values for association between renin activity

following treatment and amount of change in AHI were calculated using a

420 Pearson's correlation coefficient.

421

Table 1. Comparisons of baseline clinical characteristics

Variables	PA	Non-PA	P
Number of patients	176	418	
Age, years	57.1 ± 12.8	63.7 ± 12.2	<0.001
Male, n (%)	84 (47.7)	231 (55.3)	0.112
Body mass index, kg/m ²	25.4 ± 4.9	25.3 ± 5.2	0.682
Current smoker, n (%)	41 (23.3)	113 (27.0)	0.397
Systolic BP, mmHg	137.2 ± 15.7	131.2 ± 14.4	<0.001
Diastolic BP, mmHg	82.4 ± 10.3	76.4 ± 9.0	<0.001
LDL cholesterol, mg/dL	112.6 ± 29.4	111.8 ± 32.5	0.818
HDL cholesterol, mg/dL	54.8 ± 15.9	53.1 ± 17.0	0.273
Triacylglycerol, mg/dL	120.5 (84.0 – 165.3)	115.0 (85.0 – 171.0)	0.911
eGFR, mL/min/1.73 m ²	80.0 ± 19.2	77.6 ± 23.0	0.224
Fasting plasma glucose, mg/dL	98 (91 - 106)	101 (93 - 121)	<0.001
HbA1c (%)	5.5 (5.2 - 5.9)	5.9 (5.3 - 6.8)	<0.001
Plasma renin activity, ng/mL/hour	0.4 (0.2 - 0.6)	0.9 (0.5 - 2.1)	<0.001
Plasma aldosterone concentration, pg/mL	212.5 (153.0 – 293.8)	102.0 (63.6 – 150.0)	<0.001
Comorbidities			
Diabetes, n (%)	29 (16.5)	197 (47.1)	<0.001
Dyslipidemia, n (%)	99 (56.3)	284 (67.9)	0.009
Anti-hypertensive drugs			
Calcium channel blocker, n (%)	108 (71.5)	262 (68.8)	0.604
α blocker, n (%)	12 (7.9)	31 (8.1)	1.000

Diuretic agent, n (%)	18 (11.9)	34 (8.9)	0.375
Sleep apnea			
AHI, n (%)	10.0 (4.8-20.3)	9.7 (3.9-19.6)	0.281
Normal (<5), n (%)	47 (26.7)	125 (29.9)	0.493
Mild (5 to <15), n (%)	68 (38.6)	145 (34.7)	0.411
Moderate (15 to <30), n (%)	33 (18.8)	104 (24.9)	0.130
Severe (AHI ≥30), n (%)	28 (15.9)	44 (10.5)	0.090

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables or number (%) for categorical dichotomous variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as the mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate; AHI, apnea-hypopnea index

Table 2. Comparisons of baseline clinical characteristics among subjects divided based on degree of sleep apnea

Variables	Normal (AHI <5)	Mild (AHI 5 to <15)	Moderate (AHI 15 to <30)	Severe (AHI ≥30)	P value (Normal vs. Mild)	P value (Normal vs. Moderate)	P value (Normal vs. Severe)
Number	170	214	138	72	-	-	-
Age, years	59.3 ± 14.0	62.2 ± 11.7	64.9 ± 11.4	60.6 ± 13.8	0.026	<0.001	0.489
Male, n (%)	74 (43.5)	117 (54.7)	81 (58.7)	43 (59.7)	0.039	0.011	0.031
Body mass index, kg/m ²	22.9 ± 3.6	25.1 ± 4.7	26.1 ± 4.8	30.1 ± 6.4	<0.001	<0.001	<0.001
Current smoker, n (%)	37 (21.8)	59 (27.6)	34 (24.6)	24 (33.3)	0.235	0.646	0.083
Systolic BP, mmHg	130.2 ± 14.5	133.6 ± 15.3	133.6 ± 15.3	136.4 ± 14.3	0.024	0.045	0.002
Diastolic BP, mmHg	77.6 ± 10.1	78.9 ± 9.6	77.6 ± 9.5	78.7 ± 10.2	0.221	0.990	0.458
LDL cholesterol, mg/dL	112.8 ± 33.4	110.0 ± 31.5	113.2 ± 28.8	114.2 ± 32.5	0.540	0.930	0.798
HDL cholesterol, mg/dL	55.5 ± 18.0	54.9 ± 16.0	51.0 ± 15.1	50.3 ± 17.3	0.709	0.021	0.039
Triacylglycerol, mg/dL	102 (78 - 147)	115 (84 - 154)	125 (96 - 179)	141 (106 - 194)	0.203	0.002	<0.001
eGFR, mL/min/1.73m ²	83.0 ± 21.9	78.5 ± 21.8	75.6 ± 20.4	72.1 ± 23.6	0.043	0.002	<0.001
Fasting plasma glucose, mg/dL	97 (90 - 105)	101 (93 - 116)	104 (94 - 126)	103 (95 - 118)	0.001	<0.001	<0.001
HbA1c (%)	5.4 (5.1 - 6.0)	5.7 (5.3 - 6.6)	5.9 (5.4 - 6.8)	6.0 (5.6 - 6.8)	<0.001	<0.001	<0.001
Plasma renin activity, ng/mL/hr	0.7 (0.4 - 1.6)	0.6 (0.3 - 1.2)	0.8 (0.4 - 2.1)	0.8 (0.4 -1.7)	0.234	0.222	0.595
Plasma aldosterone concentration, pg/mL	127 (74 - 198)	121 (78 - 187)	125 (80 - 195)	147 (74 - 215)	0.812	0.662	0.718
Comorbidities							
Diabetes, n (%)	47 (27.6)	84 (39.3)	62 (44.9)	33 (45.8)	0.023	0.002	0.009

Dyslipidemia, n (%)	97 (57.1)	134 (62.6)	96 (70.0)	56 (77.8)	0.317	0.033	0.004
Anti-hypertensive drugs							
Calcium-channel blocker, n (%)	104 (68.9)	129 (67.2)	85 (69.1)	52 (78.8)	0.829	1.000	0.183
α blocker, n (%)	10 (6.6)	14 (7.3)	8 (6.5)	11 (16.7)	0.978	1.000	0.040
Diuretic agent, n (%)	8 (5.3)	23 (12.0)	14 (11.4)	7 (10.6)	0.051	0.105	0.260
Sleep apnea							
AHI	2.4 (1.1 - 3.6)	9.0 (7.1 - 11.5)	20.1 (16.7 - 24.2)	39.9 (33.0 - 45.6)	<0.001	<0.001	<0.001
PA, n (%)	45 (26.5)	69 (32.2)	34 (24.6)	28 (38.9)	0.264	0.814	0.077

Data are presented as the mean ± standard deviation or median (25th-75th percentile) for continuous variables, or number (%) for categorical variables. P values based on the two-sample Welch's t-test or Mann-Whitney U-test are shown for comparisons of location parameters, such as mean or median of two groups, or P values based on the Fisher's exact test for comparisons of percentage between groups. PA, primary aldosteronism; EH, essential hypertension; AHI, apnea-hypopnea Index; BP, blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate

Table 3. Multivariable logistic regression analysis of factors associated with degree of sleep apnea

Variables	Mild (AHI 5 to <15)		Moderate (AHI 15 to <30)		Severe (AHI ≥30)	
	OR (95%CI)	P	OR (95%CI)	P	OR (95%CI)	P
Age, years (per 5)	1.02 (0.95 - 1.11)	0.560	1.18 (1.07 - 1.30)	0.001	1.13 (1.00 - 1.05)	0.084
Male	1.16 (0.82 - 1.63)	0.410	1.29 (0.87 - 1.91)	0.212	1.56 (0.88 - 2.78)	0.130
Body mass index, kg/m ² (per 5)	0.94 (0.78 - 1.13)	0.492	1.35 (1.1 - 1.65)	0.004	2.78 (2.08 – 3.73)	<0.001
Systolic BP, mmHg (per 10)	1.03 (0.92 - 1.16)	0.615	1.04 (0.91 - 1.19)	0.566	1.11 (0.92 – 1.34)	0.275
HbA1c (%)	1.05 (0.92 - 1.20)	0.485	1.08 (0.93 - 1.25)	0.335	1.16 (0.94 - 1.43)	0.174
eGFR, mL/min/1.73 m ² (per 5)	1.00 (0.97 - 1.05)	0.708	1.00 (0.95 - 1.05)	0.897	0.93 (0.86 – 1.00)	0.045
PA (vs. non-PA)	1.28 (0.86 - 1.90)	0.229	0.97 (0.60 - 1.57)	0.905	2.08 (1.09 – 3.95)	0.025

PA, primary aldosteronism; BP, blood pressure; eGFR, estimated glomerular filtration rate; OR, odds ratio; CI, confidence interval

Subjects enrolled in HSCAA study (2010/10-2020/11) (n=1151)
Out of these, subjects with hypertensive including PA (n=781)


Excluded (n=128)
With autonomous cortisol secretion, pheochromocytoma,
primary hyperparathyroidism, eGFR<15 mL/min/1.73m², or dialysis treatment

Missing baseline data (n=59)

First analysis including subjects evaluated for sleep apnea
(total = 594, PA = 176, non-PA = 418)

Excluded (n=551)
Non-PA or no reevaluated

Final analysis including subjects with PA re-evaluated for sleep apnea and renin activity (total = 45)



● $\Delta\text{AHI}(\text{post-pre})$, amount of change — 95% prediction ellipse